Zobrazeno 1 - 10
of 109
pro vyhledávání: '"John D. Buynak"'
Autor:
Nichole K. Stewart, Marta Toth, Maha A. Alqurafi, Weirui Chai, Thu Q. Nguyen, Pojun Quan, Mijoon Lee, John D. Buynak, Clyde A. Smith, Sergei B. Vakulenko
Publikováno v:
mBio, Vol 13, Iss 3 (2022)
ABSTRACT Acinetobacter baumannii has become a major nosocomial pathogen, as it is often multidrug-resistant, which results in infections characterized by high mortality rates. The bacterium achieves high levels of resistance to β-lactam antibiotics
Externí odkaz:
https://doaj.org/article/9e0cf59bc3db4dbab2fa79a250ae777e
Autor:
Cristina Lasarte-Monterrubio, Juan C. Vázquez-Ucha, Maria Maneiro, Jorge Arca-Suárez, Isaac Alonso, Paula Guijarro-Sánchez, John D. Buynak, Germán Bou, Concepción González-Bello, Alejandro Beceiro
Publikováno v:
Antibiotics, Vol 10, Iss 2, p 210 (2021)
Treatment of infections caused by Acinetobacter spp., particularly A. baumannii, is a major clinical problem due to its high rates of antibiotic resistance. New strategies must be developed; therefore, restoration of β-lactam efficacy through the us
Externí odkaz:
https://doaj.org/article/5bf0a613c47c4d0a88f564f7b67ab07c
Autor:
Clyde A. Smith, Nichole K. Stewart, Marta Toth, Pojun Quan, John D. Buynak, Sergei B. Vakulenko
Publikováno v:
ACS Infectious Diseases. 9:1123-1136
Autor:
Noora M. S. A. Al-Kharji, Leighanne A. Brammer Basta, Pojun Quan, Maha A. Alqurafi, Thu Q. Nguyen, Phil Mortimer, Breven S. Simcox, Riya Malhotra, John D. Buynak, Rashmi Gupta, Kyle H. Rohde, Weirui Chai
Publikováno v:
ACS Infectious Diseases
Commercial carbapenem antibiotics are being used to treat multidrug resistant (MDR) and extensively drug resistant (XDR) tuberculosis. Like other β-lactams, carbapenems are irreversible inhibitors of serine d,d-transpeptidases involved in peptidogly
Autor:
Juan C. Vázquez-Ucha, Germán Bou, Jorge Arca-Suárez, Cristina Lasarte-Monterrubio, Paula Guijarro-Sánchez, M. Maneiro, Alejandro Beceiro, John D. Buynak, Isaac Alonso, Concepción González-Bello
Publikováno v:
Antibiotics
Volume 10
Issue 2
Antibiotics, Vol 10, Iss 210, p 210 (2021)
Volume 10
Issue 2
Antibiotics, Vol 10, Iss 210, p 210 (2021)
Treatment of infections caused by Acinetobacter spp., particularly A. baumannii, is a major clinical problem due to its high rates of antibiotic resistance. New strategies must be developed
therefore, restoration of β-lactam efficacy through th
therefore, restoration of β-lactam efficacy through th
Autor:
Wei Ke, Priyaranjan Pattanaik, Christopher R Bethel, Anjaneyulu Sheri, John D Buynak, Robert A Bonomo, Focco van den Akker
Publikováno v:
PLoS ONE, Vol 7, Iss 11, p e49035 (2012)
Bacterial β-lactamase enzymes are in large part responsible for the decreased ability of β-lactam antibiotics to combat infections. The inability to overcome β-lactamase mediated resistance spurred the development of inhibitors with penems and pen
Externí odkaz:
https://doaj.org/article/be647fb86f2040f48b378f09dae81ab3
Autor:
Charles J Zhang, Peter Oelschlaeger, Mohammad Faheem, William J. Welsh, Ni Ai, Antonia L. Zhang, Joon S. Kang, John D. Buynak
Publikováno v:
Journal of Chemical Information and Modeling. 58:1902-1914
The global rise of metallo-β-lactamases (MBLs) is problematic due to their ability to inactivate most β-lactam antibiotics. MBL inhibitors that could be co-administered with and restore the efficacy of β-lactams are highly sought after. In this st
Autor:
Alejandro Beceiro, Gabriel Torrens, Germán Bou, Kelly Conde-Pérez, Antonio Oliver, Juan C. Vázquez-Ucha, Concepción González-Bello, M. Maneiro, Marta Martínez-Guitián, Robert A. Bonomo, Laura Álvarez-Fraga, Margarita Poza, John D. Buynak
The carbapenem-hydrolyzing class D β-lactamases (CHDLs) are the main mechanism of carbapenem resistance in Acinetobacter baumannii. CHDLs are not effectively inactivated by clinically available β-lactam-type inhibitors. We have previously described
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d16f78a3854c21c1b4f7985f9c86859e
https://europepmc.org/articles/PMC6761515/
https://europepmc.org/articles/PMC6761515/
Autor:
Juan A. Vallejo, Germán Bou, Margarita Poza, Concepción González-Bello, Christopher R. Bethel, Juan C. Vázquez-Ucha, Marta Martínez-Guitián, John D. Buynak, Robert A. Bonomo, Alejandro Beceiro
Publikováno v:
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
instname
instname
This is a pre-copyedited, author-produced version of an article accepted for publication in Journal of Antimicrobial Chemotherapy following peer review. The version of record Juan A. Vallejo, Marta Martínez-Guitián, Juan C. Vázquez-Ucha, Concepci
Autor:
Tao Che, Paul R. Carey, Focco van den Akker, John D. Buynak, Marianne Pusztai-Carey, Sivaprakash Shanmugam, Robert A. Bonomo, Christopher R. Bethel, Weirui Chai, Zhe Ding, Michael D. Nottingham, Elizabeth A. Rodkey
Publikováno v:
Biochemistry
For the class A β-lactamase SHV-1, the kinetic and mechanistic properties of the clinically used inhibitor sulbactam are compared with the sulbactam analog substituted in its 6β position by a CH2OH group (6β-(hydroxymethyl)penicillanic acid). The